By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MAP Pharmaceuticals, Inc. 

2400 Bayshore Parkway
Suite 200
Mountain View  California  94043  U.S.A.
Phone: 650-386-3100 Fax: 650-386-3101


SEARCH JOBS


Key Statistics


Email:
Ownership: Public

Web Site: MAP Pharmaceuticals, Inc.
Employees:
Symbol: MAPP
 



Industry
Pharmaceutical






Company News
Allergan Inc. (AGN) Announces Expiration of Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. (MAPP) and Intent to Exercise Top-Up Option to Effect a Short-Form Merger 3/1/2013 9:49:48 AM
Allergan Inc. (AGN) and MAP Pharmaceuticals, Inc. (MAPP) Announce the Federal Trade Commission Has Granted Early Termination of Waiting Period Under Hart-Scott-Rodino Act 2/7/2013 9:58:14 AM
Allergan Inc. (AGN) Commences Cash Tender Offer for All Outstanding Shares of MAP Pharmaceuticals, Inc. (MAPP) 1/31/2013 10:24:52 AM
Allergan Inc. (AGN) to Buy MAP Pharmaceuticals, Inc. (MAPP) for $958 Million 1/23/2013 6:55:08 AM
MAP Pharmaceuticals, Inc. (MAPP) to Present at the 31st Annual J.P. Morgan Healthcare Conference 1/3/2013 7:28:36 AM
MAP Pharmaceuticals, Inc. (MAPP) Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX® 11/26/2012 8:46:46 AM
MAP Pharmaceuticals, Inc. (MAPP) to Present at Upcoming Investor Conferences 11/9/2012 2:15:18 PM
MAP Pharmaceuticals, Inc. (MAPP) Reports Third Quarter of 2012 Financial Results 11/2/2012 9:33:35 AM
MAP Pharmaceuticals, Inc. (MAPP) Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 10/16/2012 9:24:35 AM
MAP Pharmaceuticals, Inc. (MAPP) Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock 8/30/2012 10:17:01 AM
12345678910...
//-->